• AMBER: A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combination regimen versus a regimen consisting of darunavir/cobicistat fixed dose combination coadministered with emtricitabine/tenofovir disoproxil fumarate fixed dose combination in antiretroviral treatment-naïve human immunodeficiency virus type 1 infected subjects. (TMC114FD2HTX3001)
• Analysing humoral and cellular immune responses to vaccination during chronic infection
• Assessing the impact of introducing online postal self-sampling for sexually transmitted infections into sexual health provision within the UK on health inequalities, access to care and clinical outcomes (ASSIST)
• Attitudes to, and Understanding of Risk of Acquisition of HIV over time (AURAH2)
• BESTT Women's Study: Bone Evaluation in HIV-positive women who switch from Truvada/NNRTI to Triumeq
• British HIV Association (BHIVA) COVID-19 Registry
• CASCADE study
• Community Survey of the experiences of COVID-19 on people living with HIV in the UK
• The Co-morbidities in relation to HIV/AIDS (COBRA) study
• Data Collection on Adverse events of Anti-HIV Drugs (D:A:D)
• DISCOVER: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection (GS-US-412-2055)
• EMERALD: a randomized, active-controlled, open-label study to evaluate the efficacy and safety of switching to a D/C/F/TAF once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with FTC/TDF
• EuroCoord: Enhancing clinical & epidemiological HIV research in Europe through cohort collaboration
• EuroSIDA: A prospective observational cohort study of HIV-positive individuals in Europe, Israel and Argentina
• FLAIR: A Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
• GS-US-292-1823: A Phase 3b, Randomised, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of ABC/3TC plus a Third Antiretroviral Agent to the E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult Subjects
• GS-US-292-1826: A Phase 3b, Randomised, Open-Label Study to Evaluate Switching from a TDF Containing Regimen to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 Years
• GS-US-380-1489: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
• GS-US-380-1490: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
• HIV Allocative Efficiency and Financial Commitment Studies in Eastern Europe and Central Asia, using Optima
• HIV BioResorce
• HIV Indicator Diseases across Europe Study (HIDES)
• The HIV Modelling Consortium
• Icona Network
• MAVMET: A multicentre, 48 week randomised controlled factorial trial of adding maraviroc and/or metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapy
• Modelling and cost effectiveness analysis to inform response to high levels of HIV drug resistance in sub-Saharan Africa, including deployment of new drug regimens (HIV Synthesis Model)
• NATSAL: The National Survey of Sexual Attitudes and Lifestyles
• Needs Informed model of Care for people living with HIV (NICHE)
• NIHR HPRU: Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections
• Optimising the Public Health Benefits of Sex Work Regulation in Senegal: A Formative Study
• Outcomes of COVID-19-related hospitalization among people with HIV in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK)
• Partners of people on ART - a New Evaluation of the Risks (The PARTNER study)
• The POPPY (Pharmacokinetic and clinical Observations in PeoPle over fiftY) Study
• POPPY Sleep Substudy: study looking at the effects of being HIV positive and being on antiretroviral medication may have on sleeping and sleep pattern
• Positive Voices: The national survey of people living with HIV
• POWER Project: Protecting women from economic shocks to fight HIV in Africa
• PrEP IMPACT Trial: A pragmatic health technology assessment of PrEP and implementation
• Positive tRansItions through Menopause (PRIME)
• RESPOND: The International Cohort Consortium of Infectious Disease
• Royal Free HIV Cohort Study
• SEPAC: Screening and early detection to prevent anal cancer; development of a biomarker screening tool
• Siyaphambili Youth
• STAR HIV Self-Testing Africa
• SUPA: Supporting Uptake and adherence to antiretrovirals
• TANGO: A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically suppressed
• TB:HIV - Tuberculosis among HIV-positive Patients: An International Prospective Observational Cohort Study
• The UK Collaborative HIV Cohort (UK CHIC) Study